Sort   by:  
 Page size 
In vitro culture methods underpin many experimental approaches to biology and drug discovery. The modification of established cell culture methods to be more biologically relevant, or to optimise growth, is traditionally a laborious task. Emerging metabolomics technology enables rapid evaluation of ...
2015-05-14 | MTBLS49 | MetaboLights

Tuberculosis (TB) remains a global health threat, aggravated by the emergence of drug-resistant strains. This study aims to identify genes and metabolic pathways with increased vulnerability in drug-resistant Mycobacterium tuberculosis strains compared to their drug-susceptible counterparts. Usin...

2024-10-15 | MTBLS11277 | MetaboLights
The global prevalence of antibacterial resistance requires new antibacterial drugs with novel chemical scaffolds and modes of action. It is also vital to design compounds with optimal physicochemical properties to permeate the bacterial cell envelope. We described an approach of combining and integr...
2021-11-04 | MTBLS788 | MetaboLights
Today's high-resolution mass spectrometers (HRMS) allow bioanalysts to perform untargeted/global determinations that can reveal unexpected compounds or concentrations in a patient’s sample. This could be performed for preliminary diagnosis attempts when usual diagnostic processes and targeted ...
2019-06-06 | MTBLS476 | MetaboLights
Mass spectrometry is the current technique of choice in studying drug metabolism. High-resolution mass spectrometry (HR-MS) in combination with fragment analysis (MS/MS) has the potential to contribute to rapid advances in this field. However, the data emerging from such fragmentation spectra pose c...
2016-05-23 | MTBLS307 | MetaboLights

Chagas’ disease, caused by infection with the protozoan parasite Trypanosoma cruzi, is a potentially fatal condition for which new treatments are urgently needed. Due to the lack of validated drug targets, phenotypic screening followed by target deconvolution is the dominant approach in Chagas’ d...

2026-01-12 | MTBLS13510 | MetaboLights
HepG2 treated with 40 compounds (3 concentrations, 0.1xCmax, Cmax and 10xCmax) and vehicle for 7 h. Compounds have different degree of drug-induced liver injury concern. Data for Figure 2 in connected publication.
ORGANISM(S): Homo sapiens 
Primary human hepatocytes treated with 40 compounds (3 concentrations, 0.1xCmax, Cmax and 10xCmax) and vehicle for 7 h. Compounds have different degree of drug-induced liver injury concern. Data for Figure 2 in connected publication.
ORGANISM(S): Homo sapiens 

Background : Drug-induced liver injury (DILI) is a serious health concern that presents challenges in early detection and accurate diagnosis, thereby complicating the treatment of this liver disease. Therefore, it is crucial to explore specific biomarkers to improve the accuracy of diagnosing DIL...

2025-07-23 | MTBLS12765 | MetaboLights

The widespread use of a large number of chemicals results in a significant exposure of humans and the environment, posing potential risks to human health and ecosystems. To assess the exposure to chemical mixtures, screening applications covering a large number of analytes based on liquid chromat...

2025-10-14 | MTBLS11753 | MetaboLights
Sort   by:  
 Page size